Research

Informing Clinical Practice

Mr Addison has been involved in high quality basic-science and clinical research throughout his training and career. 

As a medical student at Cambridge University, he obtained a First Class degree, one third of which was awarded for his original laboratory research project. As a trainee in eye surgery, Mr Addison completed clinical research projects in ocular oncology at St Bartholomew’s Hospital, London and in cataract surgery at The Cambridge University Teaching Hospitals. During two years of full-time clinical and laboratory research on the molecular genetics of inherited human cataract at the UCL Institute of Ophthalmology, Mr Addison discovered novel molecular genetic causes of inherited cataracts. He was awarded his Doctorate of Medicine after completing his thesis.

As a Consultant, Mr Addison has continued to be actively involved in research, with a special interest in novel therapies to treat Medical Retinal and Uveitis disorders. He aims to ensure that his patients have access to the very latest cutting-edge therapies for their conditions, which he can deliver to them as soon as there is clinical evidence to support their use, often having been closely involved in generating that evidence or trialling those treatments in local, national and international studies. Since 2012, Mr Addison has been a co-investigator on 13 different international clinical trials including those investigating novel therapies for wet and dry age-related macular degeneration, retinal vein occlusion, uveitis and novel gene therapy for inherited eye disease. He was the principal investigator for two further studies: a national study on the genetics of steroid induced intra-ocular pressure rise and an international randomised controlled trial on central retinal vein occlusion.

Please find below a list of Mr Addison's publications and presentations:
Publications in Peer Reviewed Journals
  1. Real-World Experience of Fluocinolone Acetonide 0.19 mg in the Management of Non-Infectious Uveitis. Logeswaran A, Azzopardi M, Demir B, D’Alonzo G, Chong YT, Addison P, Pavesio C.  Ocul Immunol Inflamm. Published online July 2024.
  2. Adalimumab in the treatment of refractory non-infectious scleritis: 6 month outcomes. Bober E, Frain K, Fotuhi M, Virgo J, Hindle E, Ma J, Luis J, Addison P et al. Eye September 2023.
  3. Birdshot retinochoroiditis. Inparaj S, Testi I, Addison P.  Eye News June/July 2022; vol 29:1 
  4. Multifocal evanescent white dot syndrome-like phenotypes associated with inflammatory and myopic choroidal neovascularization. Burke T, Addison PK, Pavesio CE.  Ocul Immunol Inflamm. June 2021
  5. Severe hypotony-induced intraocular inflammation after removal of ripcord suture from a glaucoma drainage device in uveitis patient. Testi I, Addison PK, Nolan W, Pavesio CE.  Ocul Immunol Inflamm. April 2021.
  6. Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial. Patel PJ, Jayaram H, Eleftheriadou M, Vazquez-Alfageme C, Islam N, Rubin GS, Pal B, Addison PK, Hamilton R, Degli Esposti S.  Ophthalmology and Therapy September 2020; 9(3):563-576.
  7. Real-life evidence for using a treat-and-extend injection regime for patients with central retinal vein occlusion. Eleftheriadou M, Nicholson L, d’Alonzo G, Addison PKF.  Ophthalmology and Therapy April 2019; 8:289-296.
  8. What does IGRA testing add to the diagnosis of ocular tuberculosis? A Bayesian latent class analysis. Agrawal R, Grant R, Gupta B, Gunasekeran DV, Gonzalez-Lopez JJ, Addison PKF, Westcott M, Pavesio CE.  BMC Ophthalmol. 2017 Dec 8; 17(1):245.
  9. Peripheral retinal vasculitis: Analysis of 110 Consecutive Cases and a Contemporary Reappraisal of Tubercular Etiology. Agrawal R, Gunasekeran DV, Gonzalez-Lopez JJ, Cardoso J, Gupta B, Addison PK, Westcott M, Pavesio CE.   Retina 2017 Jan; 37(1):112-117.
  10.  Systematic Evaluation of Optical Coherence Tomography Angiography in Retinal Vein Occlusion. Nobre Cardoso J, Keane PA, Sim DA, Bradley P, Agrawal R, Addison PK, Egan C, Tufail A.  Am J Ophthalmol. 2016 Mar;163:93-107. 
  11. Predictive factors for treatment failure in patients with presumed ocular tuberculosis in an area of low endemic prevalence. Agrawal R, Gonzalez-Lopez JJ, Nobre-Cardoso J, Gupta B, Grant R, Addison PK, Westcott M, Pavesio CE. Br J Ophthalmol. 2016 Mar;100(3):348-55. 
  12. Spectrum of choroidal involvement in presumed ocular Tuberculosis: Report from a population with low endemic setting for Tuberculosis. Agrawal R, Gupta B, Gonzalez-Lopez J, Cardoso J, Triantafullopoulou I, Grant R, Addison PK, Westcott M, Pavesio CE.  Ocul Immunol Inflamm. 2016 Jan;1-7. 
  13. Unilateral Acute Maculopathy Associated with Adult Onset Hand Foot and Mouth Disease: Case report and review of literature. Agrawal R, Bhan K, Balaggan K, Lee R, Pavesio CE, Addison PK.  Journal of Ophthalmic Inflamm Infect. 2015 Feb 5:2.
  14. The role of anti tubercular therapy (ATT) in patients with presumed ocular tuberculosis. Agrawal R, Gupta B, Gonzalez-Lopez JJ, Rahman F, Phatak S, Triantafyllopoulou I, Addison PK, Westcott M, Pavesio CE.  Ocul Immunol Inflamm. 2015 Feb;23(1):40-6. 
  15. Optic neuropathy secondary to Linezolid for Multi Drug Resistant (MDR) mycobacterial spinal Tuberculosis. Agrawal R, Addison P, Saihan Z, Pefkianaki M, Pavesio C.  Ocul Immunol Inflamm. 2015 Feb;23(1):90-2. 
  16. A case of panuveitis with hypopyon due to presumed ocular leishmaniasis in a HIV patient. Couture S, Agrawal R, Woods K, Lockwood D, Pavesio CE, Addison PK.  J Ophthalmic Inflamm Infect. 2014 Dec;4(1):21. 
  17. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. Agrawal R, Fernandez-Sanz G, Bala S, Addison PK.  Br J Ophthalmol. 2014 Jul;98(7):961-3. 
  18. Using data from the Cataract National Dataset electronic multicentre audit to calculate risk of posterior capsule rupture and vitreous loss for patients on current surgical lists. Addison PK, Rajendram R, Bradshaw H, Hykin PG.  Eye 2011; 25:396-7.  
  19. Serous retinal detachment induced by topical bimatoprost in a patient with Sturge-Weber syndrome. Addison PK, Papadopoulos M, Nischal KK, Hykin PG. Eye 2011; 25:124-5. 
  20. A novel connexin 50 mutation associated with congenital nuclear pulverulent cataract. Arora A, Minogue PJ, Liu X, Addison PK, Russell-Eggitt I, Webster AR, Hunt DM, Ebihara L, Beyer EC, Berthoud VM, Moore AT.  J Med Genet 2008; 45:155-60.
  21. A novel mutation in the connexin 46 gene (GJA3) causes autosomal dominant zonular pulverulent cataract in a Hispanic family. Addison PK, Berry V, Holden KR, Espinal D, Rivera B, Su H, Srivastava AK, Bhattacharya SS.  Molecular Vision 2006; 12:791-5. 
  22. Vitreous relapse following primary chemotherapy for retinoblastoma: Is adjuvant diode laser a risk factor? Gombos DS, Cauchi PA, Hungerford JL, Addison P, Coen PG, Kingston JE. Br J Ophthalmol 2006; 90:1168-1172. 
  23. Clinical, molecular genetic and functional studies on inherited human cataracts. Addison PK.  MD thesis 2006 (University of London). 
  24. Posterior polar cataract is the predominant consequence of a recurrent mutation in the PITX3 gene. Addison PK, Berry V, Ionides ACW, Francis PJ, Bhattacharya SS, Moore AT.  Br J Ophthalmol 2005; 89:138-141. 
  25. Recurrent 17bp duplication in PITX3 is primarily associated with posterior polar cataract (CPP4). Berry V, Yang Z, Addison PK, Francis PJ, Ionides A, Karan G, Jiang L, Lin W, Hu J, Yang R, Moore A, Zhang K and Bhattacharya SS. J Med Genet 2004; 41(8): e109. 
  26. Radiation retinopathy secondary to radiotherapy for lower lid BCC. Addison PK, Snead DJ, Snead MP. Eye 2004; 18(12):1273-4. 
Latest Presentations at International Meetings 
  1. Managing Immunosuppressed Uveitis, Corneal, Neuro-Ophthalmic, Orbit & Adnexal Patients: A model from the largest tertiary referral centre in the United Kingdom.  Poster discussion at the annual conference of the American Academy of Ophthalmology, October 2024, Chicago, USA.
  2. Dexamethasone Implant use in Uveitis. Addison PKF.  Moorfields International Uveitis Symposium, Royal Society of Medicine, London July 2024
  3. Adalimumab in the Treatment of Refractory Non-infectious Scleritis: 18-Month Outcomes. Poster presentation at ARVO, Seattle, May 2024. Investigative Ophthalmology & Visual Science June 2024, 65:6453
  4. Adalimumab in the Treatment of Non-infectious Uveitis: A Study from the United Kingdom: Part 1 Effectiveness. Poster presentation at ARVO, Seattle, May 2024. Investigative Ophthalmology & Visual Science June 2024, 65:2601
  5. Adalimumab in the Treatment of Non-infectious Uveitis: A Study from the United Kingdom: Part 2 - Safety. Poster presentation at ARVO, Seattle, May 2024. Investigative Ophthalmology & Visual Science June 2024, 65:2605
  6. A Biologics Screening Clinic for Ocular Inflammatory Disease Patients in the United Kingdom (UK). Poster presentation at ARVO, Seattle, May 2024. Investigative Ophthalmology & Visual Science June 2024, 65:2597
  7. Optical coherence tomography biomarkers of individuals with uveitis on Adalimumab – preliminary data of a two year longitudinal analysis.  Poster presentation at ARVO, Seattle, May 2024. Investigative Ophthalmology & Visual Science June 2024, 65:3030
  8. Ocular steroid injections. Annual oral presentations since 2022 at the Moorfields Macular Course, London.
Latest Oral Presentations at Regional Ophthalmology Meetings 
 Mr Addison has taught the full range of healthcare professionals about Retinal Vein Occlusion (RVO) & Uveitis including nurses, optometrists, doctors and post-graduate students on the Ophthalmology MSc course at UCL Institute of Ophthalmology. 

 In addition to these regular teaching commitments, the following is a list of recent presentations. 
  1. The Inflammatory pathway in retinal vascular diseases.  London Fellows and Optometrists meeting, November 2024.
  2. The role of Inflammation in uveitis and RVO. Royal Victoria Hospital Dublin. Oral presentation, Royal Victoria Hospital, Dublin, September 2024
  3. Retinal vein occlusion. Oral presentation for Future Ophthalmologists Mentoring Network subsection of the UK Black Surgeons Network, April 2024
  4. Early use of intravitreal steroids in RVO and diabetic macular oedema (DMO). London & East Anglian Retinal symposium, London Bridge, January 2024
  5. Management of retinal vein occlusion. Mater Hospital, Dublin, September 2023
  6. Controversies in management of diabetic macular oedema and retinal vein occlusion. West Of Ireland regional conference, September 2023.